Showcase Your Research and Progress in COPD Drug Development
Present at the COPD Summit Poster Session
Share your latest COPD research with a focused audience of industry leaders, innovators, and decision‑makers shaping the future of respiratory drug development. The poster session is designed to foster meaningful scientific exchange in a highly collaborative, discussion‑driven environment.
This is a unique opportunity to present novel data, translational insights, and development progress across the COPD landscape, while engaging directly with peers spanning discovery, preclinical, translational, and clinical development. Whether you’re seeking expert feedback, new collaborators, or greater visibility for your work, this session connects you with those driving renewed momentum in COPD.
By presenting, you will:
- Elevate your profile within the global COPD drug development community
- Gain targeted exposure to senior biotech, pharma, and academic stakeholders
- Engage in high‑quality scientific discussion with immediate, practical feedback
- Spark new collaborations and partnership opportunities across the value chain
How to Submit Your Poster
How to Submit Your Poster
1. You must first register your place to attend the COPD Drug Development Summit
2. Submit an abstract for review to showcase your poster during the Scientific Poster Session
3. You will be notified once your abstract has been accepted along with details of printing and size requirements. We do request an online PDF of the poster 2 weeks prior to the summit
Key Information:
- Scientific Poster Session: Wednesday, September 16, 2026
- Abstract Submission Deadline: Friday, August 28, 2026
T&Cs
- Posters should not be used for sales and marketing purposes
- If your company offers pay-for services, you will need to submit your poster request to our partnerships team - sponsor@hansonwade.com
- All abstracts are subject to approval by the conference organizers, who reserve the right to reject submissions
Explore the Full Event Guide
- Network with 65+ discovery, translational, clinical and regulatory experts from the likes of Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Connect Biopharma, Generate Biomedicines, Ethris, and many more
- Critical debates on regulatory expectations and opportunities to validate novel endpoints that de‑risk development and support faster, more confident approvals
- Expert perspectives on combining imaging, molecular, and clinical data to build a more holistic view of COPD biology and improve translational success
- Hear from 16+ respiratory specialists and C-level executives presenting novel targets and clinical trial strategies
- 3 days of essential industry collaboration including over 6 hours of specialized networking
